Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Shattuck Labs Inc (STTK)

Shattuck Labs Inc (STTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,991
  • Shares Outstanding, K 47,740
  • Annual Sales, $ 1,660 K
  • Annual Income, $ -87,300 K
  • EBIT $ -80 M
  • EBITDA $ -77 M
  • 60-Month Beta 1.85
  • Price/Sales 32.84
  • Price/Cash Flow N/A
  • Price/Book 0.56

Options Overview Details

View History
  • Implied Volatility 341.84% ( +112.87%)
  • Historical Volatility 76.45%
  • IV Percentile 96%
  • IV Rank 45.63%
  • IV High 737.46% on 10/02/24
  • IV Low 9.84% on 08/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 32
  • Volume Avg (30-Day) 22
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,207
  • Open Int (30-Day) 1,499

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.46
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +7.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0850 +0.46%
on 11/20/24
1.5600 -30.13%
on 11/14/24
-0.1600 (-12.80%)
since 10/21/24
3-Month
1.0700 +1.87%
on 10/07/24
3.9500 -72.41%
on 09/30/24
-2.3400 (-68.22%)
since 08/21/24
52-Week
1.0700 +1.87%
on 10/07/24
11.7600 -90.73%
on 05/14/24
-1.2000 (-52.40%)
since 11/21/23

Most Recent Stories

More News
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

STTK : 1.0400 (-6.31%)
Insider Stock Research: New Fortress Energy, Marvell, and More

October has seen a flurry of insider trading activity across multiple sectors, with key executives making significant stock purchases. New Fortress Energy’s (

PLAY : 34.37 (+0.35%)
DKL : 39.50 (-0.33%)
RNAC : 16.80 (-0.83%)
COHR : 106.93 (+3.43%)
NEOG : 14.94 (+0.27%)
WOR : 38.80 (+0.49%)
NFE : 9.36 (+1.96%)
STTK : 1.0400 (-6.31%)
MRVL : 91.24 (+1.54%)
CAPR : 17.07 (-9.78%)
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights

– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in...

STTK : 1.0400 (-6.31%)
Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on...

STTK : 1.0400 (-6.31%)
Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - -...

STTK : 1.0400 (-6.31%)
Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the...

STTK : 1.0400 (-6.31%)
SHATTUCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Shattuck Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shattuck Labs, Inc. (NASDAQ: STTK) on behalf of long-term stockholders following...

STTK : 1.0400 (-6.31%)
STTK Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Shattuck Labs, Inc. Investors of Last Few Hours to Actively Participate in the Class Action

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK) and certain...

STTK : 1.0400 (-6.31%)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Shattuck Labs, Inc. (STTK)

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 1, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Shattuck Labs,...

STTK : 1.0400 (-6.31%)
SHATTUCK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Shattuck Labs, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Shattuck Labs, Inc. (“Shattuck” or the “Company”)...

STTK : 1.0400 (-6.31%)

Business Summary

Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North...

See More

Key Turning Points

3rd Resistance Point 1.2767
2nd Resistance Point 1.2333
1st Resistance Point 1.1717
Last Price 1.0400
1st Support Level 1.0667
2nd Support Level 1.0233
3rd Support Level 0.9617

See More

52-Week High 11.7600
Fibonacci 61.8% 7.6764
Fibonacci 50% 6.4150
Fibonacci 38.2% 5.1536
Last Price 1.0400
52-Week Low 1.0700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar